gilead is committed to ensuring that a drug's price is never a barrier to access. we support a number of programs that help ensure patients who need our therapies have access to them.
Keywords to Search:
Company Address:
333 Lakeside Dr,FOSTER CITY,CA,USA
ZIP Code: Postal Code:
94404-1147
Telephone Number:
6505789264 (+1-650-578-9264)
Fax Number:
6505743000 (+1-650-574-3000)
Website:
www. gilead. com
Email:
USA SIC Code(Standard Industrial Classification Code):
copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Gilead Sciences Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
Gilead Sciences: Company Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information
Gilead Sciences, Inc. - Investor Relations At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in
Gilead Sciences Announces First Quarter 2025 Financial Results Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6 3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3 1 billion Gilead Sciences, Inc (Nasdaq: GILD) announced today its first quarter 2025 results of operations
Gilead Sciences Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need
Newsroom | Gilead - Gilead Sciences This is our global website, intended for visitors seeking information on Gilead’s worldwide business Some content on this site is not intended for people outside the United States Visit our Global Operations page for links to our international corporate websites
Careers at Gilead Sciences Gilead, a global biopharma co pursuing innovation in virology, oncology and inflammation, offers a variety of career opportunities in an inclusive workplace where all can make an impact
Gilead Sciences Announces Completion of Acquisition of CymaBay FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc (Nasdaq: CBAY) for approximately $4 3 billion in total equity value The addition of CymaBay’s investigational lead product candidate, seladelpar for the
Gileads Livdelzi Seladelpar Granted Accelerated Approval for Primary . . . FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi ® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate
Gilead and Xilio Announce Exclusive License Agreement . . . - Gilead Sciences FOSTER CITY, Calif WALTHAM, Mass --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) and Xilio Therapeutics, Inc (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301